In this study, we tested the hypotheses that (a) functional antibodies targeting NBCn1 can be developed for specific pharmacological inhibition and (b) NBCn1 is responsible for the Na+,HCO3–-cotransport in human breast cancer tissue and can be targeted for breast cancer therapy. This evidence concerns the gene SLC4A7 and breast cancer.